3,110 reports of this reaction
5.1% of all NALTREXONE reports
#2 most reported adverse reaction
INJECTION SITE PAIN is the #2 most commonly reported adverse reaction for NALTREXONE, manufactured by Alkermes, Inc.. There are 3,110 FDA adverse event reports linking NALTREXONE to INJECTION SITE PAIN. This represents approximately 5.1% of all 60,963 adverse event reports for this drug.
NALTREXONE has an overall safety score of 78 out of 100. Patients taking NALTREXONE who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among NALTREXONE users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for NALTREXONE:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 3,110 FDA reports for NALTREXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 5.1% of all adverse event reports for NALTREXONE, making it one of the most commonly reported side effect.
If you experience injection site pain while taking NALTREXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.